View Profile

Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors Review type Summary Keywords File filename File mime type
1. 2009 Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex Clinical Cancer Research, 15(1): 48-51.
2. 2009 Interleukin-6 affects cell death escaping mechanisms acting on bax-Ku70-clusterin interactions in human colon cancer progression Cell Cycle 8(3): 1-9
3. 2009 Intratumoral Implantation of ß-Lapachone-encapsulated Polymer Millirod For Prostate Cancer Therapy. Clinical Cancer Res., 15(1): 131-139.
4. 2009 Loss of p15/Ink4b accompanies tumorigenesis triggered by particle radiation EMBO J., In Prep
5. 2009 Low-dose ionizing radiation-inducible clusterin promoter Imaging and application in biodosimetry. Manuscript in preparation, 2009.
6. 2009 Turning the superparamagnetic nanoprobes for cancer molecular imaging. Cancer Research, 69(4): 1651-8.
7. 2009 TGF-ß1 regulation of the murine double minute protein and its control of epithelial-to-mesenchymal transition. J. Clinical Investigation, In Revision,
8. 2009 Regulation of the clusterin promoter by TGF-ß1 involves Smad activation Molecular Cell, In Revision
9. 2009 ß-Lapachone micelle nanotherapeutics for non-small cell lung cancer. J. Natl Cancer Institute, Submitted.
10. 2009 CRM1-mediated nuclear export of nuclear clusterin (nCLU), a pro-death protein activated by ionizing radiation. J. Biological Chemistry, Submitted, 2009.
11. 2009 The role of DAB2IP in modulating epithelial-to-mesenchymal transition (EMT) and prostate cancer metastasis. PNAS, Submitted (Dr. G. Stark, ed.).
12. 2009 Global germline and tumor microsatellite patterns are cancer biomarkers Nature Medicine, Submitted.
13. 2009 TGF-ß-induced expression of Hdm2 correlates with late stage metastatic breast cancer J. Clinical Investigation, In Press
14. 2009 Dual PI3K/mTOR blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Research, In Press.
15. 2009 Vanadium-induced apoptosis of HaCaT cells is mediated by c-fos and involves nuclear accumulation of clusterin. FEBS J, 276(14): 3784-3799.
16. 2009 RIP1 activates PI3K-Akt via a dual mechanism involving NF-kappaB mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and downregulation of PTEN Cancer Res., 69(10): 4107-4115.
17. 2009 EGFRvIII and DNA Double-Strand Break Repair: A Molecular Mechanism for Radioresistance in Glioblastoma. Cancer Research, 69(10): 4252-4259.
18. 2009 The receptor interacting protein (RIP1) inhbits p53 induction through NF-kB activation and confers a worse prognosis in glioblastoma. Cancer Research, 69(7): 2809-2816.
19. 2008 DNA mismatch repair-dependent activation of c-Abl/p73a/GADD45a-mediated apoptosis. J. Biological Chemistry 283: 21394-21403.
20. 2008 Role of c-Abl in MMR-dependent G2 arrest responses. J. Biological Chemistry 283: 21382-21393.
21. 2007 Use of ß-lapachone for therapy against nonsmall cell lung cancer. Proc. Natl. Acad., Sci., USA 104: 11832-7.
22. 2007 NQO1-dependent ROS create threshold levels of DNA damage required for PARP-1 hyperactivation in b-lapachone-induced cell death. Free Rad. Biol., submitted.
23. 2007 Bax-inhibiting peptides derived from Ku70 and cell-penetrating pentapeptides Biochem. Soc., Trans. 35: 797-801.
24. 2007 Radiation-induced up-regulation of NAD(P)H:quinone oxidoreductase (NQO1) potentiates the effect of bioreductive ß-lapachone against cancer cells Mol Cancer Ther., 9: 634-642.
25. 2007 Modulating ß-lapachone release from polymer millirods through cyclodextrin complexation J. Control Release, 122: 365-374.
26. 2007 Nonhomologous end joining recombination is a resistance factor to NQO1- ß-lapachone Cancer Res., 67: 6936-45.
27. 2007 Clusterin over-expression modulates proapoptotic and antiproliferative effects of 1,25(OH)(2)D(3) in prostate cancer cells in vitro J. Steroid Biochemistry and Molecular Biology 103(35): 721-725.
28. 2006 Clusterin (CLU) and melanoma growth: CLU is expressed in malignant melanoma and 1,25-dihydroxyvitamin D3 modulates expression of CLU in melanoma cell lines in vitro. Anticancer Res. 26: 2707-2716.
29. 2006 Calcium regulation of PARP-1 hyperactivation for altered cellular metabolism and inhibition of DNA repair J Biological Chemistry, 261(44): 33684-33696.
30. 2006 Modulating ß-lapachone release from polymer millirods through cyclodextrin complexation. J. Pharmaceutical Sciences, 2006; 95(10): 2309-2319.
31. 2006 Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer Cell Death and Differentiation. 2006; 13(1): 12-19.
32. 2006 Multifunctional polymeric micells as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nanoletters 6 (11): 2427-2430.
33. 2005 Delayed activation of IGF-1R/Src/MAPK signaling after IR regulates clusterin expression, a pro-survival protein J. Biological Chemistry 280(14): 14212-14221.
34. 2005 Efficacy of ß-lapachone in pancreatic cancer treatment: Exploiting the novel, therapeutic target NQO1. Cancer Biology and Therapy, 4 (1): 54-61.
35. 2005 Interactions between Self-Assembled Polyelectrolyte Shells and Tumor Cells Journal of Biomedical Materials Research, 73(3): 303-312.
36. 2005 Not Mentioned Clinical Cancer Research, 11(24): 8866-8871.
37. 2005 Radiation increases the sensitivity of cancer cells to ß-lapachone. Int. J. Rad. Oncol., Biol., & Phys, 61(1): 212-219.
38. 2005 Development of β-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels Clinical Cancer Research, 11(8): 3055-3064.
39. 2005 Clusterin proteins: stress-inducible polypeptides with proposed functions in multiple organ dysfunction. British Journal of Radiology 27: 106-113.
40. 2004 Role of DNA mismatch repair in apoptotic responses to therapeutic agents. Environ. Mol. Mutagen, 44(4): 249-264.
41. 2004 DNA mismatch repair detection and cellular responses to damage caused by 5-fluoro-2’-deoxyuridine exposure J. Biological Chemistry, 280(7): 5516-5526.
42. 2004 cRGD-functionalized polymer micelles for targeted doxorubicin or ß-lapachone delivery Angew Chem. Int. Ed. Engl., 43(46): 6323-6327.
43. 2004 A phase I study of Topotecan, as a radiosensitizer for thoracic malignancies Lung Cancer 44(1): 111-119.
44. 2004 IR-inducible clusterin gene expression: a protein with potential roles in ionizing radiation-induced adaptive responses, genomic instability, and bystander effects Mutation Research, 568(1): 97-110.
45. 2004 Clusterin: a protein with multiple functions as a potential ionizing radiation exposure marker International Congress Series 27: 2784-93.
46. 2003 Synthesis and functional analyses of nuclear clusterin, a cell death protein J. Biological Chemistry 278(13): 11590-11600.
47. 2003 µ-Calpain activation in ß-lapachone-mediated apoptosis. Cancer Biology & Therapy 2(2): 141-152.
48. 2003 Enhancement of solubility and bioavailability of ß-lapachone using cyclodextrin inclusion complexes. J. Pharmacological Research 20(10): 1626-1633.
49. 2003 A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage Oncogene 22: 7376-7388
50. 2003 Transcriptional Repression of Clusterin by the p53 Tumor Suppressor Protein. Cancer Biology and Therapy 2(4): 25-31.
51. 2003 Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nature Cell Biology 5(4): 320-329.
52. 2002 Calpains and apoptosis. Korean J. Biological Science 5: 267-274.
53. 2001 ß-Lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/xip3. Experimental Cell Research 267: 95-106.
54. 2001 Calcium is a key signaling molecule in ß-lapachone-mediated cell death. J. Biological Chemistry 276(22): 19150-19159.
55. 2001 Role of DNA mismatch repair in FdUrd-mediated cytotoxicity. Cancer Research 61(13): 5193-5201.
56. 2001 Mismatch repair mediated a proficient G2 arrest and cdc2 phosphorylation following high-dose rate ionizing radiation Cancer Research 61(22): 8290-8297.
57. 2000 Coordinate modulation of Sp1, NF-kappa B, and p53 in confluent human malignant melanoma cells after ionizing radiation. FASEB Journal 14(2): 379-390.
58. 2000 Cellular and Molecular Responses to Topoisomerase I Poisons: Exploiting Synergy For Improved Radiotherapy. Annals of the New York Academy of Sciences 922: 274-292.
59. 2000 Upregulation of clusterin during photodynamic therapy-mediated apoptosis of tumor cells and ablation of mouse skin tumors. Cancer Research 60(21): 5984-5987.
60. 2000 Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death Proc. Natl. Acad. Sci., USA 97(11): 5907-5912.
61. 2000 NF-kB activation by camptothecin: A linkage between nuclear DNA damage and cytoplasmic signaling events J. Biological Chemistry 275(13): 9501-9509.
62. 2000 A novel non-caspase-mediated proteolytic pathway activated in breast cancer cells during ß-lapachone-mediated apoptosis. Experimental Cell Research 255 (2): 144-155.
63. 2000 NAD(P)H:quinone oxidoreductase (NQO1) activity is the principal determinant of ß-lapachone cytotoxicity. J. Biological Chemistry 275(8): 5416-5422.
64. 1999 bcl-2 protects against caspase 3-mediated apoptosis induced by ß-lapachone Oncology Reports 6: 485-492.
65. 1999 Delayed apoptotic responses associated with radiation-induced neoplastic transformation of human hybrid cells. Cancer Research 59(16): 3972-3979.
66. 1999 Nieman-Pick human lymphoblasts are resistant to phthalocyanine 4-photodynamic therapy-induced apoptosis. Biomedical Biophysics Research Communication 258: 506-512.
67. 1999 Combined radiation and p53 gene therapy of malignant glioma cells. Cancer Gene Therapy 6: 155-162.
68. 1999 Isolation of Ku70 binding proteins (KUBs) Nucleic Acids Research 27: 2165-2174.
69. 1999 The mismatch repair protein, hMHL1, mediates 5-substituted halogenated thymidine analog cytotoxicity, DNA incorporation and radiosensitization in human colon cancer cells. Cancer Research 59: 1840-1845.
70. 1998 Adenovirus-mediated p53 gene delivery potentiates the radiation-induced growth inhibition of experimental brain tumors. J. Neuro-Oncology 37: 217-222.
71. 1998 Molecular analyses of adaptive survival responses (ASRs): role of ASRs in radiotherapy. Human and Experimental Toxicology 17: 448-453.
72. 1998 Apoptosis, reproductive failure, and oxidative stress in Chinese hamster ovary cells with compromised genomic integrity. Cancer Research 58: 3712-3718.
73. 1998 ß-Lapachone-induced apoptosis in MCF-7 human breast cancer cells Cancer Research 58: 1876-1885.
74. 1998 DNA-dependent protein kinase (DNA-PK) does not play a role in adaptive survival responses to ionizing radiation. Perspectives in Environmental Health Sciences 106: 301-305.
75. 1998 Defective expression of the DNA mismatch repair protein, hMLH1, alters G2/M arrest following ionizing radiation. Cancer Research 58(4): 767-778.
76. 1997 Reversed-phase high-performance liquid chromatography method for determination of beta-lapachone and 3-hydroxy-beta-lapachone in plasma J. Chromatography 692 (2): 181-186.
77. 1997 Chromosome instability and its relationship to other endpoints of genomic instability. Cancer Research 57(24): 5557-5563.
78. 1997 Damage sensing mechanisms in human cells after ionizing radiation. Stem Cells 15: 27-42.
79. 1997 Cell cycle regulation of the human DNA mismatch repair genes, hMSH-2, hMLH-1 and hPMS-2. Cancer Research 57(2): 206-208.
80. 1996 Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation Int. J. Radiat. Oncol. Biol. Phys. 36(2): 361-368.
81. 1996 Altered G1 checkpoint control determines adaptive survival responses to ionizing radiation. Mutation Research 358(2): 143-153.
82. 1996 Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase I inhibitors Int. J. Radiat. Oncol. Biol. Phys. 36(2): 369-376.
83. 1996 The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: review of the synergistic effect between topotecan and radiation. J. Neuro-Oncology 30(1): 1-6.
84. 1995 ß-Lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response Cancer Research 55: 3706-3711.
85. 1994 Enhanced expression of thymidine kinase in human cells following ionizing radiation. Int. J. Rad. Oncol. Biol. Phys. 30(2): 391-398.
86. 1994 Down-regulation of topoisomerase I following ionizing radiation in mammalian cells Cancer Research 54: 4618-4626.
87. 1994 Isolation of an X-Ray-Responsive Element (XRE) in the promoter region of tissue-type plasminogen activator: potential uses of XREs for gene therapy? Radiation Research 138: 68-71
88. 1994 Alterations in transcription factor binding in radioresistant human melanoma cells following ionizing radiation. Radiation Research 138: 47-51.
89. 1994 Enhanced malignant transformation is accompanied by increased survival recovery following ionizing radiation in Chinese hamster embryo fibroblast cells. Radiation Research 138: 121-125
90. 1994 Immediate X-ray-inducible responses from mammalian cells Radiation Research 138: 44-46.
91. 1993 Isolation of X-ray-inducible transcripts from radioresistant human melanoma cells Proc. Natl. Acad. Sci., USA 90 (15): 7200-7204.
92. 1992 Posttreatment exposure to camptothecin enhances the lethal effects of X-rays on radioresistant human malignant melanoma cells. Int. J. Radiat. Oncol. Biol. Phys 24: 939-948.
93. 1992 Enhanced induction of tissue-type plasminogen activator in normal human cells compared to cancer-prone cells following ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys. 24: 949-957.
94. 1992 Regulation of gene expression in mammalian cells following ionizing radiation. Yokohama Medical Bulletin 42:137-149.
95. 1991 Effect of caffeine on the expression of a major X-ray-induced protein in human tumor cells Radiation Research 125: 313-317.
96. 1991 Induction of tissue-type plasminogen activator by ionizing radiation in human malignant melanoma cells. Cancer Research 51: 5587-5595
97. 1990 Radiation, pool size and incorporation studies in mice with 5-chloro-2'-deoxycytidine. Int. J. Radiat. Oncol. Biol. Phys. 19: 357-365.
98. 1989 Inhibition of potentially lethal DNA damage repair in human tumor cells by ß-lapachone, an activator of topoisomerase I. Cancer Research 49: 605-612.
99. 1989 Identification and characterization of X-ray-induced proteins in human cells Cancer Research 49: 2871-2878.
100. 1989 Expression of the E. coli Lac Z gene from a defective HSV-1 vector in various human normal, cancer-prone and tumor cells. FEBS Letters 258: 159-162.
101. 1989 Inhibition of radiation-induced neoplastic transformation by ß-lapachone Proc. Natl. Acad. Sci., USA 86: 4963-4967.
102. 1988 Anticarcinogenic potential of DNA-repair inhibitors. Mutation Research 202: 393-411.
103. 1987 Protective, tumor-selective dual pathway activation of 5-fluoro-2'-deoxycytidine provided by tetrahydrouridine in mice bearing mammary adenocarcinoma-755 Cancer Research 47: 2344-2353.
104. 1987 Potentiation of halogenated pyrimidine radiosensitizers by ß-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione), a novel DNA repair inhibitor Cancer Research 47: 5361-5366.
105. 1987 Tumor-selective metabolism of 5-fluoro-2'-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma Cancer Research 47: 2354-2362.
106. 1986 Analysis of 5-fluoro-2'-deoxycytidine and 5-trifluoromethyl-2'-deoxycytidine and their related antimetabolites by high performance liquid chromatography J. Chromatography 381: 343-356.
107. 1985 Metabolic channeling of 5-fluoro-2'-deoxycytidine utilizing inhibitors of its deamination in cell culture Molecular Pharmacology 27: 584-594.
108. 1985 Use of trifluoromethyl-deoxycytidine and tetrahydrouridine to circumvent catabolism and exploit high levels of cytidine deaminase in tumors to achieve DNA- and target-directed therapies. Cancer Research 45: 5270-5280.
109. 1984 Use of 5- fluorodeoxycytidine and tetrahydrouridine to exploit high levels of deoxycytidylate deaminase in tumors to achieve DNA- and target-directed therapy Cancer Research 44: 2551-2560

About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.